Legend Biotech marked a -4.2% change today, compared to 0.0% for the S&P 500. Is it a good value at today's price of $54.68? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
-
Legend Biotech belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 27.61 and an average price to book (P/B) of 3.69
-
The company's P/B ratio is 8.64
-
Legend Biotech has a trailing 12 month Price to Earnings (P/E) ratio of -35.5 based on its trailing 12 month price to earnings (EPS) of $-1.54 per share
-
Its forward P/E ratio is -78.1, based on its forward earnings per share (EPS) of $-0.7
-
Over the last four years, Legend Biotech has averaged free cash flows of $-180595666.7, which on average grew 2.0%
-
Legend Biotech has moved -18.3% over the last year compared to 24.8% for the S&P 500 -- a difference of -43.1%
-
LEGN has an average analyst rating of buy and is -33.88% away from its mean target price of $82.7 per share
